Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: Paris November 28, 2019: Bio-Modeling Systems invited to the PolePharma event "Industrie du futur" to present its collaboration with L2F the EPFL AI company adding a third dimension to AI through the Giotto program.
  • 2019: PRESS RELEASE: Paris November 6, 2019: Bio-Modeling Systems updates its pipeline of therapies, diagnostics, and bioprocesses and invites you to meet its team at BioFit and Polepharma Bio-Production conferences.
  • 2019: ANNOUNCEMENT: Lyon October 17-18, 2019: Bio-Modeling Systems invited at the India-France Knowledge Summit 2 to contribute with its CADI Discovery Platform, the other AI, successfully applied to its Indo-French   therapeutic program UMANG (now Arbuza Regenerate company) addressing  a public health issue concerning 50-100 millions children in India.
  • 2019: PRESS RELEASE: Paris October 1, 2019: Bio-Modeling Systems, the Mechanisms-Based Cosmetics company, is invited to present its CADI™ Discovery platform and 7 outputs at the open Innovation sessions of Cosmetic-360

  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO of BMSystems, joins Bolero's Pharma/Health Advisory Board to strengthen their services and accelerate the convergence between clinical research and Real Life Data

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: for the World Autism Awareness Day.
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

CADI™ Discovery - description

The Mechanisms-Based Medicine Concept:

Understanding and validating the mechanisms of a disease/disorder becomes the first objective. Finding the most adapted solutions is a necessary consequence of the first objective

  1. DISEASE/DISORDER: Describe the physiopathology of the disease/disorder with clinicians and patients feedback.
  2. MECHANISMS: Discover the causal versus symptomatic mechanisms of the disease/disorder.
  3. BIOMARKERS: Indirectly based on causal mechanisms, identify relevant biomarkers or specific combination, signatures of biomarkers (biological, imagery, physical signals, etc…) that could measure defined mechanistic deregulations at different stages of the disease/disorder.
  4. TARGETS: based on the causal mechanisms, identify what could be the best targets (not only one) to specifically address the causative deregulations.
  5. SOLUTIONS: We harness the mechanisms. Propose the most practical solutions to address the relevant mechanistic deregulations. It is important to notice that the proposed solutions, integrating diagnostics, therapies & patients follow-up, can be combinations of existing drugs, nutriments, devices, e-health, disease prevention tools and services, etc …
  6. FEED BACK LOOP: Integrate the results from e-R&D or e-Health experimentations into the validation process to improve global patient and disease/disorder follow-up.

The Life science modeling dilemma

  • The mechanisms of life are complex, non-linear and integrative.
  • In “living complex” systems, the functions of biological components and mechanisms are event and context-dependent. Classical “Cartesian” modeling concepts & approaches, valid for the majority of man-made artifacts, imply the concept of a “blue-print”. But this concept is at the opposite of biological reality.
  • While “Cartesian” Bioinformatics and Mathematical tools have proven to be efficient to collect, structure, analyze, simulate specific functions to test or generate innovative hypotheses, yet…
  • The “garbage in, garbage out” reality, tells us that the information produced and published (even in leading scientific journals) is necessarily ALWAYS incomplete, biased and erroneous to unknown extents.
  • Big Data, due to life sciences reality, generally means “Big Garbage”.
  • High value Smart Data, necessarily needs to be contextualized, with patients base-lines, and related to biological mechanisms.
  • Statistics, serendipity or massive big data cannot be the “only” medical research options to deciphering the mechanisms of complex diseases.
  • Despite increasing investments in Technology & I.T., major drugs products submissions to FDA are constantly declining.

CADI™ Discovery platform a proven operational answer, to implement Mechanisms-Based Medicine,

  • A heuristic multi-systems multi-scale systems biology approach to addresses complex, non-linear and integrative issues.
  • A revised discovery and validation process to address complex diseases issues using necessary mechanisms understanding.
  • A novel continuum between e-R&D and e-Health to enlarge and strengthen the translational medicine paradigm and extract the maximum pertinent value from scientific, medical & health data.
  • A proactive search of cost-effective solutions with lower short term failure risks exploiting the growing number of well documented off-patent molecules, multiple devices and e-health tools, disease prevention tools and services.
  • The discovery of new drugs is possible.
  • A systematic search of synergies between our research domains to optimize our proprietary CADI™ Knowledge database value through cost-effective novel applications


CADI™ Modeling : The first “heuristic” modeling approach, successfully applying its 5 principles

  1. “Architectural Principles” Approach;
  2. “Negative Selection” Process;
  3. “4 steps validation” Process;
  4. Broad life sciences & IT Expertise;
  5. “Synergic collaboration” with classical IT partners.

The second generation tools,  CADI™ Process, development started in 2002

The unique CADI™ 4 steps validation process

The CADI™ 4 steps validation process starts when the integrative biology researchers generate the initial CADI™ model

The initial CADI™ Ver.0 model is constructed by "integrative biology" researchers.

  • Step 1: For each loop, "integrative biology" researchers integrate the experimental results to generate the next CADI™ Ver. n+1 model .
  • Step 2: CADI™ model forecasts are defined by both experimental and integrative biology researchers The "experimental biology" researchers define and/or invent new innovative experimentations to test the models forecasts.
  • Step 3: "Experimental biology" researchers implement the innovative experimental approaches to test the model forecasts.
  • Step 4: Experimental results are analyzed and interpreted by both experimental and integrative biology researchers.

The CADI™ 4 steps validation process stops when no key unexpected results are reported.

The first generation (abandoned in 2001): Bio-Graph™ (1998-2001)

  • This initial "Cartesian" integrative plate-form, called "Bio-Graph™" because largely based upon graph theories, was developed over the period 1998-2001
  • This technology allowed the production of the first biological models of complex human pathologies ever produced (Tamoxifen resistance, partly with the CADI™ prototype)
  • However, this approach was extremely limited on several fronts:
    • It required that all the papers be annotated  before use, etc...
    • It required massive amounts of human intervention at all stages of the analytical process and,
    • while allowing to efficiently analyze at the cellular level, it was woefully inadequate for tasks where different tissues or organs had to be taken into consideration.
*CADI™: Computer Assisted Deductive Integration

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers